- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Interventions
- Paliperidone ER
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 14
- States / cities
- Cerritos, California • San Diego, California • Santa Ana, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 701
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colitis, Ulcerative
- Interventions
- Golimumab
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 15
- States / cities
- La Jolla, California • National City, California • Denver, Colorado + 12 more
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- ibrutinib, venetoclax, Placebo
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 14
- States / cities
- Duarte, California • La Jolla, California • Orange, California + 11 more
- Conditions
- Ulcerative Colitis
- Interventions
- Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 44
- States / cities
- Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
- Conditions
- Prostate Neoplasms
- Interventions
- Abiraterone acetate, prednisone/prednisolone or dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 3
- States / cities
- San Francisco, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Hematological Malignancies
- Interventions
- Teclistamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more
- Conditions
- Alzheimer Disease
- Interventions
- ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more
- Conditions
- Healthy
- Interventions
- Lazertinib, Itraconazole, Rifampin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Interventions
- JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Atlanta, Georgia
- Conditions
- Renal Insufficiency
- Interventions
- JNJ-56136379
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Prostatic Neoplasms
- Interventions
- Niraparib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • Riverside, California + 20 more
- Conditions
- Hepatitis C Virus
- Interventions
- Daclatasvir, Simeprevir, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more
- Conditions
- Acne Vulgaris
- Interventions
- RA-18C3
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St. Petersburg, Florida • Austin, Texas
- Conditions
- Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
- Interventions
- ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Fairfax, Virginia
- Conditions
- Sarcoma
- Interventions
- Trabectedin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 31
- States / cities
- Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
- Conditions
- Healthy Volunteers
- Interventions
- CANA/MET XR FDC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 45 more
- Conditions
- Ischemic Stroke; Ischemic Attack, Transient
- Interventions
- Milvexian, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 12,523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 127
- States / cities
- Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
- Conditions
- Fatty Liver Disease
- Interventions
- JNJ-75220795, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Hollywood, Florida • San Antonio, Texas
- Conditions
- Crohn Disease
- Interventions
- JNJ-78934804, Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 22
- States / cities
- Anaheim, California • Chula Vista, California • Los Alamitos, California + 19 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
- Conditions
- Multiple Myeloma (MM)
- Interventions
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Rivaroxaban, Placebo, Standard of Care (SOC)
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more
- Conditions
- Depressive Disorder, Major, Anhedonia
- Interventions
- Aticaprant, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Encino, California • Newport Beach, California + 26 more